These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29116597)

  • 41. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.
    Bryant KA; Frenck R; Gurtman A; Rubino J; Treanor J; Thompson A; Jones TR; Sundaraiyer V; Baxter LM; Gruber WC; Emini EA; Scott DA; Schmoele-Thoma B
    Vaccine; 2015 Oct; 33(43):5854-5860. PubMed ID: 26362099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions.
    Brodmerkel C; Zhu Y; Jiao Q; Cornacoff J; Treacy G; Mascelli MA; Gottlieb AB
    J Drugs Dermatol; 2010 Jun; 9(6):677-83. PubMed ID: 20645530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
    Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC
    Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human T lymphotropic virus type II infection and humoral responses to pneumococcal polysaccharide and tetanus toxoid vaccines.
    Jarvis GA; Janoff EN; Cheng H; Devita D; Fasching C; McCulloch CE; Murphy EL
    J Infect Dis; 2005 Apr; 191(8):1239-44. PubMed ID: 15776369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An open-label, single-arm, phase I study to evaluate the safety and immunogenicity of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, in healthy adult volunteers.
    Kim N; Choi G; Lim CY; Lee JW; Kim KH; Lee HJ
    Arch Pharm Res; 2010 Jun; 33(6):919-24. PubMed ID: 20607497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immunogenicity and safety of a tetanus-diphtheria vaccine (adult type): clinical trial in adults].
    Gil A; Dal-Ré R; González A; Lasheras L; Aguilar L; del Rey J
    Med Clin (Barc); 1995 Feb; 104(4):126-9. PubMed ID: 7898155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
    Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
    Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.
    Liu KJ; Chao TY; Chang JY; Cheng AL; Ch'ang HJ; Kao WY; Wu YC; Yu WL; Chung TR; Whang-Peng J
    J Biomed Sci; 2016 Aug; 23(1):64. PubMed ID: 27558635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.
    Ruiz-Palacios GM; Huang LM; Lin TY; Hernandez L; Guerrero ML; Villalobos AL; Van der Wielen M; Moreira M; Fissette L; Borys D; Miller JM
    Pediatr Infect Dis J; 2013 Jan; 32(1):62-71. PubMed ID: 23076383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy.
    Nived P; Nagel J; Saxne T; Geborek P; Jönsson G; Skattum L; Kapetanovic MC
    Vaccine; 2017 Jun; 35(29):3639-3646. PubMed ID: 28552512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations.
    Tseng JF; Willett CG; Fernandez-del Castillo C; Ryan DP; Clark JW; Zhu AX; Rattner DW; Winkelmann JL; Warshaw AL
    Pancreatology; 2005; 5(1):67-74. PubMed ID: 15775701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.
    Togashi T; Okada K; Yamaji M; Thompson A; Gurtman A; Cutler M; Aizawa M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2015 Oct; 34(10):1096-104. PubMed ID: 26121200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.